According to a recent LinkedIn post from BioSpectator Inc, ABL Bio is pursuing a B7-H3xROR1 bispecific antibody-drug conjugate (ADC) strategy to address limitations of existing B7-H3 ADCs, including I-DXd. The post notes that ABL206 (NEOK001) received FDA clearance for a Phase 1 trial in January, with first patient dosing anticipated around the end of May.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights comments from ABL Bio’s ADC division leadership indicating a focus on solid tumors with co-expression of B7-H3 and ROR1 to improve tumor specificity and potentially reduce toxicity in normal tissues. According to the post, preclinical data showed reduced tumor growth in models that had progressed after I-DXd, and non-human primate studies reportedly identified a high no-seen-toxic-dose level of 60 mg/kg for ABL206.
For investors, the post suggests ABL Bio is positioning ABL206 as a next-generation ADC candidate capable of addressing resistance and safety constraints seen with current B7-H3-directed therapies. If early clinical data validate the preclinical efficacy and tolerability profile, this program could enhance ABL Bio’s asset value and competitiveness within the oncology ADC segment, which has been attracting substantial partnering and licensing interest globally.